Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
Department of Pediatric Oncology and Hematology, University Hospital Cologne, Cologne, Germany.
Biom J. 2024 Oct;66(7):e202300181. doi: 10.1002/bimj.202300181.
The analysis of multiple time-to-event outcomes in a randomized controlled clinical trial can be accomplished with existing methods. However, depending on the characteristics of the disease under investigation and the circumstances in which the study is planned, it may be of interest to conduct interim analyses and adapt the study design if necessary. Due to the expected dependency of the endpoints, the full available information on the involved endpoints may not be used for this purpose. We suggest a solution to this problem by embedding the endpoints in a multistate model. If this model is Markovian, it is possible to take the disease history of the patients into account and allow for data-dependent design adaptations. To this end, we introduce a flexible test procedure for a variety of applications, but are particularly concerned with the simultaneous consideration of progression-free survival (PFS) and overall survival (OS). This setting is of key interest in oncological trials. We conduct simulation studies to determine the properties for small sample sizes and demonstrate an application based on data from the NB2004-HR study.
在随机对照临床试验中,对多个时依结局进行分析可以使用现有的方法来完成。然而,根据所研究疾病的特征和研究计划的情况,进行中期分析并在必要时调整研究设计可能会很有意义。由于终点的预期依赖性,可能无法充分利用涉及的终点的全部可用信息来实现此目的。我们通过将终点嵌入多状态模型来解决这个问题。如果该模型是马尔可夫的,则可以考虑患者的疾病史并允许进行数据依赖的设计调整。为此,我们为各种应用引入了灵活的检验程序,但特别关注同时考虑无进展生存期(PFS)和总生存期(OS)。这种设置在肿瘤学试验中至关重要。我们进行模拟研究以确定小样本量的性质,并基于 NB2004-HR 研究的数据展示一个应用示例。